Gilead to buy Immunomedics for $21bn
Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.
LSPN Connect: Invention harvesting
In the fast-paced environment of life sciences, the need for the IP sector to take full advantage of potential and emerging innovations is paramount, as a LSPN Connect session discovered.
Amyris facing $881m lawsuit over claims it broke contract
Cannabinoid maker Lavvan has filed a $881 million trade secrets lawsuit against pharmaceutical company Amyris.
EU concludes COVID-19 vaccine talks with Pfizer
The European Commission has concluded exploratory talks with Pfizer and BioNTech to potentially supply 300 million doses of their investigational vaccine against COVID-19.
Ruling opens door for Noven’s oestrogen patch generics
In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
Fed Circ grants Arthrex remand, rejects Iancu conflict
The US Court of Appeals for the Federal Circuit granted the owner of an artificial heart valve patent a remand under Arthrex, but shot down the company’s attempt to escape an inter partes review by citing a conflict.
CRISPR babies still too risky, warns new report
Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel.
Moderna’s COVID-19 and Zika patent applications to be investigated
A US Department of Health and Human Services agency will investigate whether Moderna disclosed information on government funding in patent applications relating to its COVID-19 vaccine.
FTC demands AbbVie divests Crohn’s treatment in Allergan buyout
The US Federal Trade Commission has approved a final order regarding charges that biopharmaceutical company AbbVie’s $63 billion acquisition of Allergan would violate US federal antitrust law.
LSPN Connect: Protecting biologics at home and abroad
Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern.
